VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 76 filers reported holding VAXCYTE INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $96,813,783 | -3.2% | 2,019,057 | -51.6% | 31.54% | -7.8% |
| Q3 2022 | $100,049,000 | +10.3% | 4,168,718 | 0.0% | 34.21% | +17.8% |
| Q2 2022 | $90,711,000 | -9.7% | 4,168,718 | 0.0% | 29.04% | +1.8% |
| Q1 2022 | $100,508,000 | +1.3% | 4,168,718 | 0.0% | 28.51% | +18.7% |
| Q4 2021 | $99,174,000 | -6.2% | 4,168,718 | 0.0% | 24.03% | +0.1% |
| Q3 2021 | $105,760,000 | +13.0% | 4,168,718 | 0.0% | 24.00% | -17.1% |
| Q2 2021 | $93,629,000 | +14.0% | 4,168,718 | 0.0% | 28.94% | +2.0% |
| Q1 2021 | $82,124,000 | -25.8% | 4,168,718 | 0.0% | 28.36% | -25.1% |
| Q4 2020 | $110,721,000 | -46.2% | 4,168,718 | 0.0% | 37.88% | -14.0% |
| Q3 2020 | $205,851,000 | +56.5% | 4,168,718 | 0.0% | 44.03% | +19.7% |
| Q2 2020 | $131,523,000 | – | 4,168,718 | – | 36.77% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |